AIM
GNMX

Alambic Investment Management’s Aevi Genomic Medicine Inc GNMX Stock Holding History

Alambic Investment Management’s Portfolio GNMX Stock Details GNMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-22,575
Closed -$42K – 728
2017
Q1 		$42K Buy
+22,575
New +$102K 0.01% 623
2016
Q1 		– Sell
-11,220
Closed -$68K – 546
2015
Q4 		$68K Buy
+11,220
New +$76.2K 0.04% 347

Other funds holding GNMX

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
2L
22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
ECM
Element Capital Management New York $1.05B AUM 5.05% 1-Year Est. Return

Alambic Investment Management's GNMX Position: Q2 2017 in Review

Alambic Investment Management sold out of Aevi Genomic Medicine Inc (GNMX) in Q2 2017, closing a stake of 22,575 shares — an estimated $42K sold.

Alambic Investment Management first reported a position in GNMX in Q4 2015 and held it in 2 quarters. The position peaked at $68K in Q4 2015. 51 funds tracked by Wall St. Rank hold GNMX as of Q2 2017.

  • Alambic Investment Management reported no remaining Aevi Genomic Medicine Inc position as of Q2 2017 after selling out during the quarter.
  • Alambic Investment Management sold 22,575 Aevi Genomic Medicine Inc shares in Q2 2017, an estimated $42K.
  • Alambic Investment Management first reported a position in Aevi Genomic Medicine Inc in Q4 2015 and held it in 2 quarters.
  • Alambic Investment Management's Aevi Genomic Medicine Inc position peaked at $68K in Q4 2015.
  • 51 funds tracked by Wall St. Rank held Aevi Genomic Medicine Inc as of Q2 2017.

Based on Alambic Investment Management's 13F filing for Q2 2017, filed 14 Aug 2017.